CureVac N.V. (Nasdaq: CVAC) today announced positive preliminary data from ongoing Phase 1 clinical programs in COVID-19 and seasonal flu, assessing both modified and unmodified mRNA technology.
The company hosted a conference call and webcast. Please find below the download link for the press release and the presentation slides as well as the link to the on demand version of the webcast.